Companies · Pharmaceuticals

ND Acquisitions Corp.

NASHVILLE · Pharmaceuticals

Diligence memoA one-page analyst read on ND Acquisitions Corp. — recommendation, valuation, rhythm, risks.
$51.6M
Total raised · real
9
Rounds
0.3×
Latest step-up
Top 19%
Sector rank · raised
Series A
Latest stage · inferred · Tue Mar 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

ND Acquisitions Corp. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.61× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.
Dormant
  • Last raise 11.3 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

ND Acquisitions Corp. is one of 1610 Pharmaceuticals companies tracked from NASHVILLE. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2009-05-08 Raised $5.5M (real) Modeled valuation $170M (est)Series A2009Series A · 2010-09-27 Raised $1.5M (real) Modeled valuation $46M (est)Series A2010Series A · 2011-02-25 Raised $5.0M (real) Modeled valuation $155M (est)Series A2011Series A · 2011-09-09 Raised $12M (real) Modeled valuation $379M (est)Series A2011Series A · 2012-07-13 Raised $2.0M (real) Modeled valuation $62M (est)Series A2012Series A · 2013-01-16 Raised $1.9M (real) Modeled valuation $60M (est)Series A2013Series A · 2013-06-11 Raised $8.5M (real) Modeled valuation $264M (est)Series A2013Series A · 2013-06-11 Raised $11M (real) Modeled valuation $342M (est)Series A2013Series A · 2015-03-10 Raised $3.8M (real) Modeled valuation $119M (est)Series A2015+$1.5M+$5.0M+$12M+$2.0M+$1.9M+$8.5M+$11M+$3.8MCumulative $52M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.5M · 2009
Series A extension$1.5M · 2010
Series A extension$5.0M · 2011
Series A extension$12.2M · 2011
Series A extension$2.0M · 2012
Series A extension$1.9M · 2013
Series A extension$8.5M · 2013
Series A extension$11.0M · 2013
Series A extension$3.8M · 2015

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$119.2M
Base estimate est.
$4.4M
Conservative case
$648.3M
Upside case
$17.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $169.5M · 2009-05-082009Series A · modeled $46.5M · 2010-09-27Series A · modeled $154.9M · 2011-02-25Series A · modeled $378.6M · 2011-09-09Series A · modeled $61.9M · 2012-07-13Series A · modeled $60.3M · 2013-01-16Series A · modeled $264.2M · 2013-06-11Series A · modeled $341.7M · 2013-06-11Series A · modeled $119.2M · 2015-03-102015
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
11.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$8.8M/yr
Capital velocity
17.1 yr
On record since
2009
First round
9
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 6.4× above median
This company$51.6M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.7× of median
This company$3.8M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 1.6× above median
This company$119.2M
Sector median$76.1M

Raised more than 82% of sector peers (real $). Modeled value above 58% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #49 of 64.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Aquinox Pharmaceuticals (Usa) Inc · Series A Raised $30.6M · modeled $433.6M (est)Neurovia, Inc. · Series A Raised $13.9M · modeled $432.1M (est)Romark Global Pharma, LLC · Series A Raised $13.8M · modeled $428.5M (est)Access Pharmaceuticals Inc · Series A Raised $39.2M · modeled $423.2M (est)OncoQuest Inc. · Series A Raised $13.0M · modeled $402.6M (est)Minnesota Medical Solutions LLC · Series A Raised $16.6M · modeled $402.6M (est)Immune Pharmaceuticals Inc · Series A Raised $11.7M · modeled $363.0M (est)Great Lakes Pharmaceuticals, Inc. · Series A Raised $11.2M · modeled $347.5M (est)Rhythm Holding Company, LLC · Series A Raised $11.0M · modeled $340.7M (est)Pharmatrophix Inc · Series A Raised $16.8M · modeled $319.0M (est)Vesuvius Pharmaceuticals, Inc. · Series A Raised $10.2M · modeled $316.7M (est)CoStim Pharmaceuticals Inc. · Series A Raised $10.0M · modeled $309.9M (est)ND Acquisitions Corp. (this company) Raised $51.6M · modeled $119.2M (est)ND Acquisitions Corp.
CompanyStageRaised · realValue · estvs peer med.
Aquinox Pharmaceuticals (Usa) IncSeries A$30.6M$433.6M2.21×
Neurovia, Inc.Series A$13.9M$432.1M2.20×
Romark Global Pharma, LLCSeries A$13.8M$428.5M2.18×
Access Pharmaceuticals IncSeries A$39.2M$423.2M2.16×
OncoQuest Inc.Series A$13.0M$402.6M2.05×
Minnesota Medical Solutions LLCSeries A$16.6M$402.6M2.05×
Immune Pharmaceuticals IncSeries A$11.7M$363.0M1.85×
Great Lakes Pharmaceuticals, Inc.Series A$11.2M$347.5M1.77×
Rhythm Holding Company, LLCSeries A$11.0M$340.7M1.74×
Pharmatrophix IncSeries A$16.8M$319.0M1.62×
Vesuvius Pharmaceuticals, Inc.Series A$10.2M$316.7M1.61×
CoStim Pharmaceuticals Inc.Series A$10.0M$309.9M1.58×
ND Acquisitions Corp. this companySeries A$51.6M$119.2M0.61×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.5M2009-05-08$24.9M$169.5M90%
Series A$1.5M2010-09-27$6.8M$46.5M90%
Series A$5.0M2011-02-25$22.7M$154.9M90%
Series A$12.2M2011-09-09$55.6M$378.6M90%
Series A$2.0M2012-07-13$9.1M$61.9M90%
Series A$1.9M2013-01-16$8.9M$60.3M90%
Series A$8.5M2013-06-11$38.8M$264.2M90%
Series A$11.0M2013-06-11$50.1M$341.7M90%
Series A$3.8M2015-03-10$17.5M$119.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.5M2009-05-08
    • First recorded raise — entered as Series A.
  2. Series A$1.5M2010-09-27
    • Raised 17 mo later, in step with the ~13 mo sector norm.
    • Round 3.6× smaller than the prior — bridge or down round.
  3. Series A$5.0M2011-02-25
    • Came back fast: 5 mo vs the ~13 mo sector norm.
    • Round 3.3× larger than the prior — scaling up.
  4. Series A$12.2M2011-09-09
    • Came back fast: 6 mo vs the ~13 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
  5. Series A$2.0M2012-07-13
    • Raised 10 mo later, in step with the ~13 mo sector norm.
    • Round 6.1× smaller than the prior — bridge or down round.
  6. Series A$1.9M2013-01-16
    • Came back fast: 6 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
  7. Series A$8.5M2013-06-11
    • Came back fast: 5 mo vs the ~13 mo sector norm.
    • Round 4.4× larger than the prior — scaling up.
  8. Series A$11.0M2013-06-11
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  9. Series A$3.8M2015-03-10
    • Raised again after 21 mo — slower than the ~13 mo sector norm.
    • Round 2.9× smaller than the prior — bridge or down round.
Intelligence
2015 ~Q4
Modeled next raise · ~9mo cadence
$3.8M
Modeled next size est.range $3.8M$6.2M
0.3×
Last step-up
$8.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Matthew A> King13 other2010-09
Matthew King7 other2009-05
David A> Kaufman1 other2011-09
Dennis Bottorff1 other2009-05
Donald Taylor1 other2013-01
Ken A> Woody1 other2011-09
C. Daniel Haron2013-06
Chris Daniel Maness2013-06
Chris Maness2013-01
Dennis C. Bottorff2013-06
Dennis Reed Bottorff2010-09
Donald Reed Taylor2010-09
Edgardo A. Mercadante2010-09
James Reed McKnight, Jr.2010-09
James Usdan2009-05
Jim Beaumariage2013-01
Jim Daniel Beaumarriage2013-06
Joseph Keane2009-05
Kenneth M. Krakaur2013-06
Linwood A Lacy2010-09
Linwood A. Lacy, Jr.2013-06
Linwood Lacy2009-05
Mary Daniel Howard2013-06
Registry & provenance

ND Acquisitions Corp. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1464225
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Enable Dental Inc.HealthtechSeries A$21.9M$62.1Mnetwork2 shared operators · same stage
Spine BioPharma, Inc.PharmaceuticalsSeries A$51.8M$63.8Msame sector · same stage
Provectus Biopharmaceuticals, Inc.PharmaceuticalsSeries A$49.9M$50.5Msame sector · same stage
VBI Vaccines Inc/BCPharmaceuticalsSeries A$41.6M$145.6Msame sector · same stage
Eyegate Pharmaceuticals IncPharmaceuticalsSeries A$72.9M$92.5Msame sector · same stage
Edo Interactive IncOtherSeries B$73.0M$328.6Mnetwork2 shared operators
Hoth Therapeutics, Inc.PharmaceuticalsSeries A$33.7M$100.5Msame sector · same stage
Can-Fite BioPharma Ltd.PharmaceuticalsSeries A$82.2M$160.1Msame sector · same stage
Frequently asked
How much funding has ND Acquisitions Corp. raised?
ND Acquisitions Corp. has raised approximately $51.6M in disclosed capital across 9 recorded financing rounds, aggregated from public filings.
What is ND Acquisitions Corp.'s estimated valuation?
Provath's modeled valuation for ND Acquisitions Corp. is approximately $119.2M (modeled range $4.4M–$648.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ND Acquisitions Corp. at?
ND Acquisitions Corp.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Mar 10.
What does ND Acquisitions Corp. do and where is it based?
ND Acquisitions Corp. operates in the Pharmaceuticals sector, based in NASHVILLE.
Explore related

See where ND Acquisitions Corp. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ND Acquisitions Corp., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.